Listing & Compliance Notices

FEMASYS INC received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“May 19, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that for the last 30 consecutive business days, the Market Value of Listed Securities (“MVLS”) for the Company’s common stock was below the minimum $35.0 million requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”). Additionally, the Company does not meet either of the alternative Nasdaq continued listing standards under Nasdaq Listing Rule 5550(b)(2): (i) stockholders’ equity of at least $2.5 mill”

MARIN SOFTWARE INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 21, 2025, Marin Software Incorporated, a Delaware corporation (the “Company”), received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 and its continued failure to file the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form”

Value Exchange International, Inc. received a otc deficiency notice notice regarding late filing.

“May 19, 2025. The stock still trades under the symbol “VEII.” The Company intends to reapply for listing on the OTCQB marketplace once it has filed with the Securities and Exchange Commission all applicable periodic filings. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VALUE EXCHANGE INTERNATIONAL, INC., a Nevada corporation By: /s/ Tan Seng Wee Kenneth Date: May 21, 2025 Tan Seng Wee Kenneth, Chief Executive Officer and President”

PCB BANCORP received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 22, 2025, PCB Bancorp (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasda”

Midland States Bancorp, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 19, 2025, the Company received an expected notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it does not comply with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”) because of the continued delinquency in filing the Form 10-K and the delinquency in filing the Form 10-Q. The Notice has no immediate effect on the listing or trading of the Company’s common stock or depositary shares on the Nasdaq Global Select Market. In accordance with Nasdaq’s listing rules, the Company has until June 2, 2025 to submit to Nasdaq a plan to regain complianc”

ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2025, Artelo Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ equity of $652,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of t”

Avalon GloboCare Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2025, Avalon GloboCare Corp. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($3,891,270), as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, was below the required minimum of $2.5 million, and because, as of May 22, 2025, the Compa”

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 23, 2025, Moleculin Biotech, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does not h”

Q32 Bio Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“May 19, 2025, Q32 Bio Inc. (“Q32 Bio” or the “Company”) received written notice (the “Notice”) from the listing qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 which reported the Company’s stockholders’ equity (deficit) of approximately ($4.0 million), the Company is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market per Listing Rule 5550(b)(1). Additionally, t”

urban-gro, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 21, 2025, urban-gro, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (the “Form 10-Q”) or its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”), the Company continues to be out of compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commi”

Corvex, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 20, 2025, Movano Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Form 10-Q was due on May 15, 2025. The Notice states that the Company has 60 ca”

Triller Group Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“le or Standard; Transfer of Listing. On May 20, 2025, Triller Group Inc. (“Triller”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “ Filing ”). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exch”

Sunnova Energy International Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“May 20, 2025, Sunnova Energy International Inc. (the “Company”) received a notice (the “Notice”) from the staff of NYSE Regulation of the New York Stock Exchange (the “NYSE”) indicating that the Company is now subject to the procedures set forth in Section 802.01E of the NYSE Listed Company Manual (the “Manual”) due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). The NYSE informed the Company that, under Section 802.01E of the Manual, the Company has until November 19, 2025 to”

Brand Engagement Network Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 21, 2025 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file the Quarterly Report. The Company has 60 calendar days from May 21, 2025, or until July 20, 2025, to regain compliance by filing the Quarterly Report or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. The Company intends to file the Quarterly Report as soon as possible. If the Company is unable to file the Quarterly Report by July 20, 2025, the Company intends to submit a plan w”

Healthcare Triangle, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

“May 20, 2025, Healthcare Triangle, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the Company’s issuance of securities pursuant to the Company’s private placement, dated February 27, 2025”

Biofrontera Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)).

“May 21, 2025, Biofrontera Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended March 31, 2025 was $469,000, the Company is no longer in compliance with the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000. Additionally, as of the date of the Notice, the Company did not meet either of the alternative requirements of”

reAlpha Tech Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 20, 2025, reAlpha Tech Corp. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days beginning on April 7, 2025, and ending on May 19, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), th”

Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C)).

“”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar”

Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

“”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar”

Alto Ingredients, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 19, 2025, Alto Ingredients, Inc. (the “Company”) received a letter from the listing qualifications staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, ending November 15, 2025, to regain compliance. The letter states that the Nasdaq staff will provide written notification that”

Scienture Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“May 19, 2025, Scienture Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock, par value $0.0001 (“Common Stock”) had been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). According to that notice, the Company has 180 calendar days, or until November 17, 2025, to regain compliance with the Minimum Bid Price Requirement. To”

CIMG Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 19, 2025, the Company received a notice (the “Quarterly Report Notice”) from NASDAQ indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 with the Securities and Exchange Commission (the “SEC”). The Quarterly Report Notice has no immediate effect on the listing of the Company’s stock on Nasdaq. Previously, NASDAQ had granted the Company an exception until June 13, 2025, to file its delinquent Form 10-K for the period ended September 30, 2024 (the “In”

Aptevo Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2025, Aptevo Therapeutics Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ deficit of $1,473,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing o”

Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 20, 2025, Onconetix, Inc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “ 10-Q ”), and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. As previously reported in the Current Report on Form 8-K filed with the Secur”

Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2), 5810(c)(3)(A)(iii), 5810(d)).

“May 20, 2025, Petros Pharmaceuticals, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of (i) the Company’s failure to maintain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), (ii) the Company’s failure to meet the minimum bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2), (iii) the Company’s low bid price pursuant to Nasdaq Listing Rule 5810(”

IRIDEX CORP received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). As described in the Notice, the Company’s last reported stockholders’ equity as of March 29, 2025, was approximately $852,000 and, as of May 14, 2025, the Company does not meet the alternative listing requirements of its market value of listed securities or its net income from continuing operations in”

Sow Good Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 14, 2025, Sow Good Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”), indicating that, based on the closing bid price for the previous 30 consecutive business days, the listing of the Company's common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until November 10, 2025 (the “Compliance Date”), to regain compliance. If at any time during”

INTENSITY THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 19, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities o”

Imunon, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 19, 2025, Imunon, Inc. (“the Company”) received a letter (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is no longer in compliance with the minimum stockholders’ equity requirement (the “Minimum Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000 or meet the alternative compliance standards relating to the market value of listed securities or ne”

EQUUS TOTAL RETURN, INC. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“May 15, 2025, Equus Total Return, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Common Stock from the NYSE. The Company plans to notify the NYSE by May 25, 2025 that it intends to cure the average closing stock price deficiency and to return to compliance with the N”

REGIONAL HEALTH PROPERTIES, INC received a nyse_american delisting notice notice regarding stockholders equity (rules 1009(a), 1003(a)(i)).

“(the “Common Stock”), and Regional’s Series A Redeemable Preferred Shares, no par value (the “Series A Preferred Stock” and, together with the Common Stock, the “Securities”) from NYSE American. The Staff had previously determined that Regional was no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as Regional was unable to demonstrate that it had regained compliance with Sections 1003(a)(i) and (ii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on November 10, 2024. Regional reques”

AppTech Payments Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 16, 2025, the Company was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined to delist the Company’s common stock and warrants from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock and warrants effective at the open of business, on May 20, 2025. Nasdaq further indicated that it would file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “ SEC ”). The Company has applied and been ap”

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 16, 2025, Plus Therapeutics, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). Nasdaq’s notice has no immediate effect on the listing or trading of the Company’s common stock. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided an initial compliance period of 180 ca”

XWELL, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 13, 2025, XWELL, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between March 31, 2025, to May 12, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until November 10, 20”

AIxCrypto Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 19, 2025, Qualigen Therapeutics, Inc. (the “Company”) received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on May 19, 2025 (the “Notice”). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market . This matter serves as an additional deficiency under Nasdaq Listing Rule 5250(c)(1), which require”

Pineapple Financial Inc. received a nyse_american delisting notice notice regarding minimum bid price (rules 1003(f)(v)).

“May 14, 2025, NYSE American LLC (“ NYSE American ” or the “ Exchange ”) publicly announced and provided a notice to Pineapple Financial Inc. (the “ Company ”) that the NYSE Regulation has suspended trading of, and determined to commence proceedings to delist, the Company’s common shares, no par value per share (the “ Common Shares ”), from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide (the “ Company Guide ”) due to the low selling price of the Common Shares. The Company has a ri”

Aureus Greenway Holdings Inc received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“May 16, 2025, the Company received a letter from Nasdaq notifying the Company that based on the Company’s Quarterly Report on Form 10-Q filed on May 15, 2025, evidencing stockholders’ equity of $11,247,542, Nasdaq has determined that the Company complies with the Minimum Stockholder’s Equity Requirement and the deficiency matter has been closed. Forward-Looking Statements This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking st”

OLENOX INDUSTRIES INC. received a nasdaq delisting notice notice regarding other (rules 5101).

“May 13, 2025, Safe & Green Holdings Corp. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the Company’s issuance of securities pursuant to the securities purchase agreement dated April 14, 2025”

BIG 5 SPORTING GOODS Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“May 13, 2025, Big 5 Sporting Goods Corporation (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 10, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00”

LIPELLA PHARMACEUTICALS INC. received a nasdaq noncompliance notice notice regarding other (rules 5635(d), 5640).

“on to its investment bank for placement agent and related consulting and advisory services received in connection with the Company’s private placement transactions conducted between December 2024 and March 2025, the Staff has determined that the Company failed to comply with (i) Nasdaq Listing Rule 5635(d), which requires prior shareholder approval for the issuance, other than in a public offering, of 20% or more of a company’s outstanding shares at a per share price less than the Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) (the “Shareholder Approval Rule”) and (ii) Nasdaq”

QVC Group, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price.

“May 16, 2025, the Company notified Nasdaq of its decision to voluntarily delist QVCGB from The Nasdaq Capital Market and its intent to file a Form 25 with the U.S. Securities and Exchange Commission (the “SEC”) on or about May 27, 2025. The Company has applied for QVCGB to be quoted on the OTCQB Venture Market (“OTCQB”), and it intends to take such actions to enable QVCGB to be quoted on the OTCQB or on another market operated by OTC Markets Group Inc. (“OTC”), so that a trading market may continue to exist for QVCGB. There is no guarantee, however, that a broker will continue to make a market”

Ondas Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 16, 2025, Ondas Holdings Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 12, 2025”

Hoth Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 13, 2025, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Ba”

BioAtla, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

“May 12, 2025, BioAtla, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that because the Company’s stockholders’ equity was $547,000 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, it was no longer in compliance with the $10,000,000 minimum stockholders’ equity requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(1)(A) (the “Minimum Stockholder Equity Requirement”), and th”

Empery Digital Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“May 13, 2025, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the minimum closing bid price per share for its common stock was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The letter states that pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(”

Grove Collaborative Holdings, Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).

“May 15, 2025, Grove Collaborative Holdings, Inc. (the “Company”) received notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the requirement of Section 802.01B of the New York Stock Exchange Listed Company Manual (the “NYSE Manual”) that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders’ equity of not less than $50.0 million (the “NYSE Notice”). Pursuant to the NYSE Notice, the Company is subject to the procedures set forth in Sections 801 and 802 of the NYSE Manual and”

Dermata Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“May 14, 2025, the Company received a letter from the Staff indicating that as of May 14, 2025, the Company has regained compliance with the Stockholder’s Equity Requirement and the matter is now closed. Minimum Bid Price On May 14, 2025, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation”

Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 14, 2025, the Company received a letter from the Staff indicating that as of May 14, 2025, the Company has regained compliance with the Stockholder’s Equity Requirement and the matter is now closed. Minimum Bid Price On May 14, 2025, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation”

MultiSensor AI Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 15, 2025, MultiSensor AI Holdings, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Comp”

Direct Digital Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“received a notice (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that because the closing bid price of the Company’s Class A common stock, par value $0.001 per share (the “ Class A Common Stock ”) was below $1.00 per share for the prior 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). The Notice states that the Company has 180 calendar”